IRIS In ASD Misses Primary, But Pivoting To Irritability; -004 Was Not In Model

Research evidence excerpt

IRIS In ASD Misses Primary, But Pivoting To Irritability; -004 Was Not In Model

regulatory expectation for a non-inferiority or comparative trial

versus risperidone or aripiprazole, although generic availability may create step-edit dynamics

if ML-004 ultimately reaches market pending final data. The company also suggested the

future clinical path is likely to focus primarily on ASD irritability, potentially with a restricted

adolescent population and appropriate baseline severity threshold (though MPLT highlighted

even though prior agents restricted entry to more severely irritated participants in a trial

setting, the eventual label is broader). While we await further details on the development plan

and FDA interactions, the combination of established ABC-I precedent, relatively efficient

historical study designs, and a potential tolerability advantage makes investigating the

therapy interesting.

Additional Mechanistic Context

Mechanistically, ML-004 is an immediate-release / extended-release reformulation of

zolmitriptan, a 5-HT1B/1D agonist currently approved for the acute treatment of migraine.

Maplight’s translational rationale has emphasized preclinical effects in both sociability and

irritability/aggression animal models, with 5-HT1B activity implicated in social reward circuitry

and suppression of striatal circuits linked to aggression.

Management noted on the call that the social communication and aggression / irritability

effects may be mediated by different circuits, with the aggression effect tied to D1 medium

spiny neurons, and that it remains unclear whether the miss on ABI-SC reflects failure of an

unproven endpoint or absence of drug efficacy in social communication. Exploratory eye-

tracking analyses are still being evaluated.